FDA accepts BridgeBio's NDA for oral infigratinib for achondroplasia
Tweet Send to a Friend
BridgeBio Pharma (Nasdaq: BBIO) announced that the U.S. Food and Drug Administration has accepted for filing its New Drug Application ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




